NCT07513571

A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of AZD4954 and Vice Versa in Healthy Adults

An Open-label Study to Assess the Effect of AZD0780 on the Pharmacokinetics of AZD4954 and Vice Versa in Healthy Adults.

• Status: Not Yet Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 32 (estimated)
• Sponsor: AstraZeneca · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The purpose this study is to measure the impact of laroprovstat (AZD0780) on the pharmacokinetics (PK) of AZD4954 and the impact of AZD4954 on the PK of laroprovstat in healthy male and female participants.

Detailed description

This is an open-label, fixed-sequence, 2 period and 2 cohort study in healthy participants. Each participant in each cohort will receive treatments in a fixed order during the 2 treatment periods as follows: * Cohort 1: Treatment A followed by Treatment C. * Cohort 2: Treatment B followed by Treatment C. The following treatments will be given during the study: * Treatment A: single dose of AZD4954 alone. * Treatment B: single dose of laroprovstat alone. * Treatment C: single doses of laroprovstat + AZD4954. The study will comprise of a Screening Period, two Treatment Periods and follow-up visits.

Conditions

• Healthy Participants

Interventions

Type	Name	Description
DRUG	AZD4954	AZD4954 will be administered orally.
DRUG	Laroprovstat	Laroprovstat will be administered orally.

Timeline

• Start date: 2026-04-10
• Primary completion: 2026-07-09
• Completion: 2026-07-09
• First posted: 2026-04-07
• Last updated: 2026-04-07

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study